

## Special Issue

# Probiotics and Prebiotics 2015

### Message from the Guest Editor

Probiotics are defined as live non-pathogenic bacteria that beneficially affect the host by influencing the microbiota of the digestive tract. Prebiotics, that are usually saccharides and fiber, represent a source of energy being metabolized by the intestinal and probiotic microbiota. In the last several decades, a rapid rise in the use of probiotics/prebiotics occurred for prevention and treatment of diseases in medicine, such as diarrhea caused by certain pathogenic bacteria and viruses, *Helicobacter pylori* infection, and allergies, etc. Rigid evidence supporting the efficacy of probiotics/prebiotics in such clinical uses and mechanical studies are now needed in order to firmly establish them in modern medicine.

---

### Guest Editor

Prof. Dr. Yasuhiro Koga

Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan

---

### Deadline for manuscript submissions

closed (15 April 2015)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/3258](http://mdpi.com/si/3258)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)